CN102068419A - Curcumin composition - Google Patents
Curcumin composition Download PDFInfo
- Publication number
- CN102068419A CN102068419A CN2010106099192A CN201010609919A CN102068419A CN 102068419 A CN102068419 A CN 102068419A CN 2010106099192 A CN2010106099192 A CN 2010106099192A CN 201010609919 A CN201010609919 A CN 201010609919A CN 102068419 A CN102068419 A CN 102068419A
- Authority
- CN
- China
- Prior art keywords
- curcumin
- ionic surface
- fatty acid
- agent
- compositions according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 title claims abstract description 234
- 235000012754 curcumin Nutrition 0.000 title claims abstract description 116
- 239000004148 curcumin Substances 0.000 title claims abstract description 116
- 229940109262 curcumin Drugs 0.000 title claims abstract description 116
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 title claims abstract description 116
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 39
- -1 curcumin phospholipid compound Chemical class 0.000 claims abstract description 23
- 239000004094 surface-active agent Substances 0.000 claims description 18
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 16
- 239000000194 fatty acid Substances 0.000 claims description 16
- 229930195729 fatty acid Natural products 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 150000002148 esters Chemical class 0.000 claims description 10
- 150000004665 fatty acids Chemical class 0.000 claims description 7
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 claims description 6
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 4
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 4
- 150000002170 ethers Chemical class 0.000 claims description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 4
- 239000005639 Lauric acid Substances 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 claims description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 244000173166 Pyrus ussuriensis Species 0.000 claims description 2
- 235000011572 Pyrus ussuriensis Nutrition 0.000 claims description 2
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims description 2
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 claims description 2
- 150000007942 carboxylates Chemical class 0.000 claims description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 235000011067 sorbitan monolaureate Nutrition 0.000 claims description 2
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000002736 nonionic surfactant Substances 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000008347 soybean phospholipid Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 235000012424 soybean oil Nutrition 0.000 description 4
- 239000003549 soybean oil Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229940042880 natural phospholipid Drugs 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229940051841 polyoxyethylene ether Drugs 0.000 description 2
- 229920000056 polyoxyethylene ether Polymers 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- AOZUYISQWWJMJC-UHFFFAOYSA-N acetic acid;methanol;hydrate Chemical compound O.OC.CC(O)=O AOZUYISQWWJMJC-UHFFFAOYSA-N 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000037358 bacterial metabolism Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000003632 chemoprophylactic effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000010226 intestinal metabolism Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a curcumin composition. The composition comprises the following components in part by weight: 1 part of curcumin phospholipid compound, and 0.6 to 2.5 parts of nonionic surfactant, wherein the curcumin phospholipid compound consists of 1 part of curcumin, and 0.4 to 1.8 parts of phospholipid. The combined components have remarkable synergetic effect, and can remarkably improve the bioavailability of the curcumin.
Description
Technical field
The present invention relates to pharmaceutical product, specifically a kind of Chinese medicine composition that contains plant extract.
Background technology
Curcumin is a kind of phenolic compound that extracts from the conventional Chinese medicine Rhizoma Curcumae Longae, also is present in other zingiberaceous plant.Modern study finds that curcumin has wide biological activity and pharmacological action, as blood fat reducing, atherosclerosis, antiplatelet aggregation, inflammation-inhibiting reaction, antioxidation, resisting rheumatoid disease etc., curcumin is used to prevent and treat the tumor that various derivants cause as chemoprophylactic drug and obtains extensive studies in recent years, and animal model test confirms curcumin safety, effectively.But because the curcumin utmost point is insoluble in water, do not dissolve to highly acid (stomach) aqueous medium at weak acid (duodenum and small intestinal), therefore common curcumin preparation (as curcumin sheet, curcumin capsule) is difficult for absorbing at gastric, and during through intestinal easily by enzyme in the intestinal or bacterial metabolism.So existing curcumin preparation exists absorption difference, problem that bioavailability is low.
In order to improve the bioavailability of curcumin, there is research worker to carry out curcumin and phospholipid compound, physicochemical property and biological nature to curcumin improves thus, make and had dispersibility preferably, promoted medicine to absorb, can improve the bioavailability of curcumin effectively at gastrointestinal.Disclose a kind of phospholipid complexes of curcumin as CN200410036402.3, the bioavailability of this complex is higher relatively, but still remains further to be improved.
Summary of the invention
Purpose of the present invention is exactly that a kind of new curcumin compositions will be provided, with the further dispersion of curcumin, the absorption rate and the bioavailability of medicament of raising curcumin improved.
The object of the present invention is achieved like this:
Curcumin compositions provided by the present invention is made of the component of following weight part ratio:
1 part of phospholipid complexes of curcumin, non-ionic surface active agent 0.6-2.5 part; Phospholipid complexes of curcumin wherein part is made of 1 part of curcumin, phosphatidase 10 .4～1.8.
The more preferred proportioning of phospholipid complexes of curcumin is by 1 part of curcumin, phosphatidase 10 .4～0.8 part.
Wherein phospholipid can be selected natural phospholipid or synthetic phospholipid for use.Natural phospholipid is optional from soybean phospholipid or egg phosphatide, and synthetic phospholipid can be selected from two palmityl phosphatidyl cholines or two palmityl PHOSPHATIDYL ETHANOLAMINE.
Above-mentioned non-ionic surface active agent is one or more the mixture in the agent of ethers non-ionic surface, esters non-ionic surface active agent or the high score subclass non-ionic surface active agent.
The mixture of one or more in ethers non-ionic surface agent preferred fatty acid polyoxyethylene ether, the polyoxyethylene lauryl ether;
One or more mixture of esters non-ionic surface active agent preferred fatty acid Pyrusussuriensis ester, lauric acid polyoxy glycol glyceride, sucrose fatty acid ester, polyoxyethylene carboxylate, Span-20, sorbitan fatty acid ester, sorbitan fatty acid ester ethylene oxide adduct; Wherein sucrose fatty acid ester more helps absorption of human body, is easy to biodegradation so be highly preferred non-ionic surface active agent among the present invention.
The mixture of one or more in Arlacel-20, Arlacel-40, the Arlacel-80 more preferably in the sorbitan fatty acid ester.
The mixture of one or more in tween 80, the tween 20 more preferably in the sorbitan fatty acid ester ethylene oxide adduct.
In the agent of high score subclass non-ionic surface more preferably molecular weight be the poloxalkol of 4000-8000.
The present invention constitutes compositions with phospholipid complexes of curcumin and non-ionic surface active agent, can effectively improve the bioavailability of curcumin, but the raising of its bioavailability and the non-linear relation of the consumption of surfactant, when phospholipid complexes of curcumin adds the amount of surfactant 〉=0.6, its bioavailability increases along with the increase of dosage of surfactant, and when the amount of surfactant greater than 2.5 the time, bioavailability does not then have significant change again.So the invention provides phospholipid complexes of curcumin and the effective proportional quantity of non-ionic surface active agent, both improved the bioavailability of curcumin with this, therefore the consumption of non-ionic surface active agent can be controlled at reasonable category again, also avoid the excessive and inconvenience that bring to preparation process of non-ionic surface active agent consumption.
Each component is share and is had significant synergism in the present composition, therefore under the fixed situation of curcumin consumption, can effectively reduce the consumption of phospholipid.As among the present invention the phospholipid in the phospholipid complexes of curcumin being reduced to 0.4～0.8 part, can significantly improve the bioavailability of curcumin.
Curcumin compositions of the present invention can be prepared in order to the below method:
Curcumin extraction, phospholipid, 1: 0.4～1.8 weight part ratio are taken by weighing each component, curcumin extraction is mixed with phospholipid after the back adds the appropriate amount of organic dissolving, after decompression or the spray drying, obtain phospholipid complexes of curcumin; Be 1 according to phospholipid complexes of curcumin and non-ionic surface active agent weight part ratio again: 0.6-2.5 takes by weighing each component, with the two mix homogeneously.Add pharmaceutically acceptable pharmaceutic adjuvant such as diluent, absorbent, binding agent, wetting agent, disintegrating agent, lubricant and slow-release material at last, stirring or ground and mixed are even, are prepared into acceptable clinically various dosage forms.
Above-mentioned organic solvent can be selected from chloroform, ether, acetone, dichloromethane, ethyl acetate, dioxane, oxolane, normal hexane, C1-C6 straight or branched low-grade alkane alcohol (as methanol, ethanol, propanol or butanols) etc.
The medical usage of the present composition and usage, consumption all can be with reference to the curcumin soft capsules.
Description of drawings
Fig. 1 is blood drug level-time plot in the rat body.
Among the figure:
The specific embodiment
Following examples are used for that the present invention is further illustrated, but with this protection scope of the present invention are not limited.
The preparation of embodiment 1 curcumin composition soft
Prescription: phospholipid complexes of curcumin 140.g (curcumin: soybean phospholipid=1: 0.4)
Sucrose fatty acid ester 135g
Soybean oil 1485g
Make 1000
Get gelatin, water and glycerol and be mixed with gelatin solution, be incubated standby.
After taking by weighing curcumin and soybean phospholipid adding anhydrous alcohol solution by weight proportion, make phospholipid complexes of curcumin after the spray drying, with the sucrose fatty acid ester mix homogeneously, being dissolved in must yellow clear and bright medicinal liquid in the soybean oil.The medicinal liquid for preparing is added in the feed tank, carry out pelleting, dry under 24-30 ℃, relative humidity 20-45% condition, promptly get the curcumin composition soft.
The preparation of embodiment 2 curcumin composition sustained-release sheets
Prescription: phospholipid complexes of curcumin (curcumin: two palmityl phosphatidyl cholines=1: 0.8)
180g
Arlacel-20 180g
Hypromellose 150g
Calcium hydrogen phosphate 60g
Pregelatinized Starch 150g
The 1.0%PVP alcoholic solution is an amount of
Magnesium stearate 40g
Make 1000
Take by weighing curcumin and two palmityl phosphatidyl cholines by weight proportion, with the two mixing, after adding the chloroform dissolving, decompression makes phospholipid complexes of curcumin, grinds with calcium hydrogen phosphate and Arlacel-20, after making it fully absorb liquid, with phospholipid complexes of curcumin, hypromellose, pregelatinized Starch mix homogeneously, with an amount of 1.0%PVP alcoholic solution system soft material, 18 mesh sieves are granulated, 60 ℃ of dry back granulate, with recipe quantity magnesium stearate mix homogeneously, tabletting, promptly get curcumin composition sustained-release sheet.
The preparation of embodiment 3 curcumin composition oral liquid
Prescription: phospholipid complexes of curcumin 100g (curcumin: egg yolk lecithin=1: 1.0)
Lauric acid polyoxyethylene ether 100g
Icing Sugar 800g
Mannitol 400g
Carmethose 8g
Sodium benzoate 4g
Essence is an amount of
Purified water 1500g
Make 1000
Take by weighing curcumin by weight proportion and egg yolk lecithin makes phospholipid complexes of curcumin, recipe quantity Icing Sugar, mannitol, carmethose, sodium benzoate is soluble in water, add phospholipid complexes of curcumin and polyoxyethylene lauryl ether, after suspendible is even, add an amount of essence, promptly get curcumin composition oral liquid.
The preparation of embodiment 4 curcumin composition softs
Prescription: phospholipid complexes of curcumin 100g (curcumin: soybean phospholipid=1: 1.25)
Polyoxyethylene sorbitan monoleate 135g
Soybean oil 1485g
Make 1000
Get gelatin, water and glycerol and be mixed with gelatin solution, be incubated standby.Take by weighing curcumin by weight proportion and soybean phospholipid makes phospholipid complexes of curcumin, with the polyoxyethylene sorbitan monoleate mix homogeneously, be dissolved in the soybean oil yellow clear and bright medicinal liquid.The medicinal liquid for preparing is added in the feed tank, carry out pelleting, dry under 24-30 ℃, relative humidity 20-45% condition, promptly get the curcumin composition soft.
Prescription: phospholipid complexes of curcumin 100g (curcumin: soybean phospholipid=1: 1.8)
Tween 20 60g
Distilled water 1000ml
Make 1000ml
Take by weighing curcumin by weight proportion and soybean phospholipid makes phospholipid complexes of curcumin, the recipe quantity tween 20 is slowly added, add an amount of correctives, make suspension.
Beneficial effect of the present invention has obtained checking by following test.
Test example 1
Dosage regimen: the SD rat, male, body weight 180-230g.Purify and feed 7d, fasting 12h, whole process be can't help water.Distinguish 5 groups at random, every group 10, be respectively curcumin group (giving curcumin), phospholipid complexes of curcumin group (giving phospholipid complexes of curcumin), curcumin compositions A organizes (curcumin compositions shown in the embodiment 1), curcumin compositions B organizes (curcumin compositions shown in the embodiment 2), curcumin compositions C organizes (curcumin compositions shown in the embodiment 3), each group is scattered in the radiacmeter of 0.2g/kg curcumin in 0.5% the carboxymethylcellulose sodium solution, make the suspension oral gavage administration, respectively at 0.08,0.25,0.5,0.75,1,1.5,2,2.5,3,4,5h gets blood 0.5ml from rat eye socket venous plexus.
Sample treatment: blood sample is placed the centrifugal 5min of centrifuge tube 1200r/min that scribbles the anticoagulant heparin agent, get 0.2ml blood plasma, add 0.5ml chromatograph methanol, vortex vibration 30s, the centrifugal 5min of 12000r/min, protein precipitation, extract curcumin, supernatant is measured the concentration of curcumin through HPLC.
Chromatographic condition: chromatographic column DiamonsilC18 (4.6mm * 250mm, 5 μ m); Mobile phase methanol-water-acetic acid (77: 22: 1); Detect wavelength 428nm; Flow velocity 1.0ml/min, column temperature are room temperature.
Curcumin blood drug level data see Table 1 in the rat body, are abscissa with the sample time, and the concentration of curcumin is vertical coordinate in the blood plasma, mapping, and blood medicine (curcumin) concentration-time curve is seen Fig. 1 in the rat body.
Curcumin blood drug level (μ g/ml) in the table 1 rat body
Date processing: use the 3P97 medicine to handle for calculation procedure, the curcumin compositions of match meets the one compartment model one-level at the rat physiological disposition and absorbs, with AUC, the C of curcumin compositions and curcumin and phospholipid complexes of curcumin
Max, T
Max3 parameters have been carried out variance analysis and q check, and both kinetic parameters compare between any two, AUC, C
MaxSignificant difference (P＜0.05) is arranged.Relevant pharmacokinetic parameters sees table 2 for details.
Table 2 pharmacokinetic parameters (
N=10)
Annotate: * P＜0.05
The result shows that the degree of absorption of simple curcumin suspension is relatively poor, and the bioavailability of phospholipid complexes of curcumin increases, compositions provided by the invention, AUC, C
MaxAll be higher than phospholipid complexes of curcumin (P＜0.05), curcumin compositions provided by the invention blood drug level height in the rat body is described, can significantly improve curcumin, more help curcumin and bring into play drug effect in vivo in the intravital relative bioavailability of rat.
Claims (8)
1. curcumin compositions is characterized in that it is made of the component of following weight part ratio:
1 part of phospholipid complexes of curcumin, non-ionic surface active agent 0.6-2.5 part, phospholipid complexes of curcumin wherein part is made of 1 part of curcumin, phosphatidase 10 .4～1.8.
2. curcumin compositions according to claim 1 is characterized in that described phospholipid complexes of curcumin by 1 part of curcumin, phosphatidase 10 .4～0.8 part formation.
3. curcumin compositions according to claim 1 is characterized in that described non-ionic surface active agent is one or more the mixture in the agent of ethers non-ionic surface, the agent of esters non-ionic surface or the agent of high score subclass non-ionic surface.
4. curcumin compositions according to claim 3 is characterized in that the agent of described ethers non-ionic surface is one or more the mixture in aliphatic acid polyethenoxy ether, the polyoxyethylene lauryl ether.
5. curcumin compositions according to claim 3 is characterized in that described esters non-ionic surface active agent is one or more a mixture of fatty acid Pyrusussuriensis ester, lauric acid polyoxy glycol glyceride, sucrose fatty acid ester, polyoxyethylene carboxylate, Span-20, sorbitan fatty acid ester, sorbitan fatty acid ester ethylene oxide adduct.
6. curcumin compositions according to claim 5 is characterized in that described sorbitan fatty acid ester is one or more the mixture in Arlacel-20, Arlacel-40, the Arlacel-80.
7. curcumin compositions according to claim 5 is characterized in that described sorbitan fatty acid ester ethylene oxide adduct is one or more the mixture in tween 80, the tween 20.
8. curcumin compositions according to claim 3 is characterized in that the agent of described high score subclass non-ionic surface is the poloxalkol of molecular weight 4000-8000.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010106099192A CN102068419A (en) | 2010-12-28 | 2010-12-28 | Curcumin composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010106099192A CN102068419A (en) | 2010-12-28 | 2010-12-28 | Curcumin composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102068419A true CN102068419A (en) | 2011-05-25 |
Family
ID=44027299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010106099192A Pending CN102068419A (en) | 2010-12-28 | 2010-12-28 | Curcumin composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102068419A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3203992A4 (en) * | 2014-10-08 | 2018-11-07 | Boston Biopharm, Inc. | Compositions and methods for increasing the bioavailability of one or more compounds |
| JP2018193307A (en) * | 2017-05-12 | 2018-12-06 | 小林製薬株式会社 | Curcuminoid-containing tablets |
| CN109481689A (en) * | 2018-12-25 | 2019-03-19 | 广州白云山汉方现代药业有限公司 | Water-soluble composition of a kind of enhancing curcumin and preparation method thereof |
| CN110960516A (en) * | 2018-09-27 | 2020-04-07 | 广州汝丽多食品科技有限公司 | Curcumin compound and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1657040A (en) * | 2004-11-22 | 2005-08-24 | 山东大学 | Curcumin phospholipid complex and preparation method thereof |
| CN1772011A (en) * | 2005-11-04 | 2006-05-17 | 张钧寿 | Ginkgo leaf extract composition and its prepn |
| US20090131373A1 (en) * | 2006-03-09 | 2009-05-21 | Andrea Giori | Phospholipid complexes of curcumin having improved bioavailability |
| CN101618222A (en) * | 2008-06-30 | 2010-01-06 | 成都国嘉联合制药有限公司 | Anethol trithione and phospholipid compound and preparation method thereof |
-
2010
- 2010-12-28 CN CN2010106099192A patent/CN102068419A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1657040A (en) * | 2004-11-22 | 2005-08-24 | 山东大学 | Curcumin phospholipid complex and preparation method thereof |
| CN1772011A (en) * | 2005-11-04 | 2006-05-17 | 张钧寿 | Ginkgo leaf extract composition and its prepn |
| US20090131373A1 (en) * | 2006-03-09 | 2009-05-21 | Andrea Giori | Phospholipid complexes of curcumin having improved bioavailability |
| CN101618222A (en) * | 2008-06-30 | 2010-01-06 | 成都国嘉联合制药有限公司 | Anethol trithione and phospholipid compound and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| 《International Journal of Pharmaceutics》 20071231 Kuntal Maiti etc. Curcumin-phospholipid complex: Preparation,therapeutic evaluation and pharmacokinetic study in rats 第330卷, 2 * |
| 《中国中药杂志》 20080930 刘安昌 等 姜黄素磷脂复合物的制备及其形成机制研究 第33卷, 第17期 * |
| 《临沂医专学报》 19961231 张梅玉 等 表面活性剂对药物吸收的影响 第18卷, 2 * |
| 刘安昌 等: "姜黄素磷脂复合物的制备及其形成机制研究", 《中国中药杂志》, vol. 33, no. 17, 30 September 2008 (2008-09-30) * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3203992A4 (en) * | 2014-10-08 | 2018-11-07 | Boston Biopharm, Inc. | Compositions and methods for increasing the bioavailability of one or more compounds |
| US11185507B2 (en) | 2014-10-08 | 2021-11-30 | Boston Biopharm Inc. | Compositions and methods for increasing the bioavailability of one or more compounds |
| JP2018193307A (en) * | 2017-05-12 | 2018-12-06 | 小林製薬株式会社 | Curcuminoid-containing tablets |
| CN110960516A (en) * | 2018-09-27 | 2020-04-07 | 广州汝丽多食品科技有限公司 | Curcumin compound and preparation method thereof |
| CN110960516B (en) * | 2018-09-27 | 2023-01-06 | 广州汝丽多食品科技有限公司 | Curcumin compound and preparation method thereof |
| CN109481689A (en) * | 2018-12-25 | 2019-03-19 | 广州白云山汉方现代药业有限公司 | Water-soluble composition of a kind of enhancing curcumin and preparation method thereof |
| CN109481689B (en) * | 2018-12-25 | 2021-12-03 | 广州白云山汉方现代药业有限公司 | Composition for enhancing water solubility of curcumin and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019205118B2 (en) | Modified release composition comprising a cannabinoid | |
| EP2846768B1 (en) | Granulate containing cannabinoid, method for its manufacture and oral dosage unit comprising such granulate | |
| AU4490900A (en) | Beta-carboline pharmaceutical compositions | |
| US10660856B2 (en) | Porous silica gel as a carrier for liquid technologies | |
| CN105708799A (en) | Nano-structural lipid carrier pharmaceutical composition and preparation method thereof | |
| CN103893258B (en) | Oral solid formulation and its application containing Desmodium styracifolium general flavone | |
| CN1320926C (en) | Ginkgo leaf extract composition and its prepn | |
| CN102973528B (en) | Calcitriol solid lipidic dispersion and preparation method thereof | |
| CN102068419A (en) | Curcumin composition | |
| CN102846544A (en) | Self-microemulsion composition of insoluble medicine | |
| CN101780037A (en) | Dipyridamole self-emulsifying medicament administration system and preparation method thereof | |
| CN101340882A (en) | Method of producing drug-containing wax matrix particles, extruder to be used in the method and sustained-release preparation containing cilostazol | |
| CN101143142A (en) | Silybin supersaturated self-emulsion composition and preparation method thereof | |
| CN101530399B (en) | Silibinin solid self-emusifying tablet | |
| CN104710433B (en) | Chlorambucil derivative, preparation method and application | |
| CN102058537B (en) | Oryzanol solid dispersion composition and preparation thereof | |
| CN102188417A (en) | Dronedarone medicinal composition | |
| CN102614182A (en) | Solid preparation of compound ammonia phenol renin medicine composition liposome | |
| CN109620809A (en) | A kind of preparation method of Instant Gefitinib tablet medicament composition | |
| CN102058538B (en) | Cycloartenyl ferulate solid dispersion and preparation thereof | |
| CN101618222B (en) | Anethol trithione and phospholipid compound and preparation method thereof | |
| CN103690482A (en) | Glycyrrhizic acid self-emulsifying preparation concentrated solution using phospholipid complex as intermediate and preparation method thereof | |
| CN101259100B (en) | Etoposide preparations and preparation thereof | |
| CN103169691A (en) | Dronedarone or powder of salt thereof and pharmaceutical composition prepared therefrom | |
| CN102697765B (en) | Ranitidine hydrochloride/bismuth potassium citrate pharmaceutical composition solid lipid nanoparticles preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: South Luancheng County 051430 Hebei city of Shijiazhuang Province Applicant after: China Shineway Pharmaceutical Group Co., Ltd. Address before: South Luancheng County 051430 Hebei city of Shijiazhuang Province Applicant before: Shineway Pharmaceutical Co., Ltd. |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: SHINEWAY PHARMACEUTICAL CO., LTD. TO: SHINEWAY PHARMACEUTICAL GROUP LIMITED |
|
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20110525 |